Skip to Main Content

Preston C. Sprenkle, MD

Associate Professor of Urology; Co-Chair, Cancer Liaison Committee, Oncology; Co-Chair, NCCN Guidelines Committee on Prostate Cancer Early Detection; Division Chief, Division of Urology at VA Connecticut Healthcare System, Urology; Director, Urology Research Fellowship, Urology; Director, Urologic Oncology Clinical Fellowship Program, Urology

Research Summary

Integration of prostate imaging and genomics for more personalized diagnosis and treatment of prostate cancers. collaborate with translational scientists and machine learning specialists to develop predictive models utilizing multiple clinical factors to improve diagnostic predictions and modeling.

Extensive Research Description

Improving accuracy of prostate cancer diagnosis, staging, and treatment through enhanced imaging techniques with Prostate MRI and targeted prostate biopsies using our clinical outcomes database.

Clinical trial interventions on patients with high risk prostate cancer as well as utilizing new techniques and technologies for ablation (destruction) of prostate cancer using such technologies as cryoablation, irreversible electroporation, TULSA, laser ablation, and others.

Research Interests

Magnetic Resonance Imaging; Prostatectomy; Urology; Genomics; Ablation Techniques; High-Intensity Focused Ultrasound Ablation; Machine Learning

Clinical Trials

ConditionsStudy Title
ProstateA Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer
ProstateRandomized Three-Arm Trial to Evaluate the Effect of Neoadjuvant Apalutamide Alone or in Combination With Abiraterone Acetate and GnRH Agonist on Enhancing Surgical Outcome of Nerve-Sparing Radical Prostatectomy in Men With High-Risk Prostate Cancer
Other Male Genital; ProstateCustomized Ablation of the Prostate With the TULSA Procedure Against Radical Prostatectomy Treatment: a Randomized Controlled Trial for Localized Prostate Cancer (CAPTAIN)
ProstateSIMCAP (Surgery in Metastatic Carcinoma of Prostate): Phase 2.5 Multi-Institution Randomized Prospective Clinical Trial Evaluating the Impact of Cytoreductive Radical Prostatectomy Combined With Best Systemic Therapy on Oncologic and Quality of Life Outcomes in Men With Newly Diagnosed Metastatic Prostate Cancer
ProstateEvaluation of the TULSA-PRO MRI-Guided Transurethral Ultrasound Prostate Ablation Device in Patients With Localized Prostate Cancer: a Prospective, Single-Arm, Pivotal Clinical Study
ProstatePhase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
ProstateMR-US Image Fusion Targeted Biopsy for Single-cell Prostate Cancer Research
ProstateActive Surveillance in Prostate Cancer, Imaging to Detect Radiographic Progression as an Endpoint (ASPIRE)